Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
| dc.contributor.author | Lenz, H | |
| dc.contributor.author | Philip, P | |
| dc.contributor.author | Saunders, Mark P | |
| dc.contributor.author | Kolevska, T | |
| dc.contributor.author | Mukherjee, K | |
| dc.contributor.author | Samuel, L | |
| dc.contributor.author | Bondarde, S | |
| dc.contributor.author | Dobbs, T | |
| dc.contributor.author | Tagliaferri, M | |
| dc.contributor.author | Hoch, U | |
| dc.contributor.author | Hannah, A | |
| dc.contributor.author | Berkowitz, M | |
| dc.date.accessioned | 2017-11-23T20:52:25Z | |
| dc.date.available | 2017-11-23T20:52:25Z | |
| dc.date.issued | 2017-12 | |
| dc.identifier.citation | Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. 2017, 80(6): 1161-1169 Cancer Chemother Pharmacol | en |
| dc.identifier.issn | 1432-0843 | |
| dc.identifier.pmid | 29043412 | |
| dc.identifier.doi | 10.1007/s00280-017-3438-y | |
| dc.identifier.uri | http://hdl.handle.net/10541/620685 | |
| dc.description.abstract | Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). This phase II study compared EP versus irinotecan as second-line treatment for KRAS-mutant, irinotecan-naïve, metastatic colorectal cancer (mCRC). | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Cancer chemotherapy and pharmacology | en |
| dc.title | Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. | en |
| dc.type | Article | en |
| dc.contributor.department | USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave Rm 3456, Los Angeles, CA | en |
| dc.identifier.journal | Cancer Chemotherapy and Pharmacology | en |
| html.description.abstract | Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). This phase II study compared EP versus irinotecan as second-line treatment for KRAS-mutant, irinotecan-naïve, metastatic colorectal cancer (mCRC). |